Group 1 - Bayer's oral contraceptive Youshuai® 84-pack has successfully completed import clearance and is launched on Alibaba Health, aiming to enhance medication convenience and adherence for women's long-term health management [1] - The "Consensus on Clinical Application of Combined Oral Contraceptives in China" has been initiated, focusing on improving women's awareness of the importance of medication adherence in disease management [3] - The low usage rate of combined oral contraceptives (COC) among women of childbearing age in China is attributed to fear of hormonal drugs and insufficient understanding, leading to missed opportunities for effective health benefits [3] Group 2 - Youshuai® is a short-acting oral contraceptive approved in China since December 2014, featuring a "24+4" dosing regimen, suitable for contraception and treatment of moderate acne in females aged 14 and above [3] - The launch of Youshuai® 84-pack is expected to reduce the frequency of medication purchases and improper discontinuation, thereby enhancing patient adherence and continuity of treatment [3] - Alibaba Health provides a comprehensive online healthcare service system, ensuring convenient access to medications and maintaining treatment continuity through efficient nationwide delivery [4]

Core Insights - Bayer's oral contraceptive Youshu Yue in a 84-tablet pack has successfully completed import customs clearance and is launched on Alibaba Health, aiming to enhance medication convenience and adherence for women's health management [1][3] - The launch coincides with the initiation of the "Consensus on Clinical Application of Combined Oral Contraceptives in China," which emphasizes the importance of medication adherence in disease management for women [3] Group 1: Product Launch and Features - Youshu Yue is designed to cover a complete three-month medication cycle, addressing the actual needs of long-term health management for women [1] - The product is a short-acting oral contraceptive approved in China since December 2014, featuring a "24+4" dosing regimen, which includes 24 active tablets and 4 inactive tablets [3] - It is indicated for contraception and treatment of moderate acne in females aged 14 and above without known contraindications for oral contraceptives [3] Group 2: Market Context and Challenges - The usage rate of combined oral contraceptives (COCs) among women of childbearing age in China is notably low, primarily due to fears of hormonal medications and insufficient understanding of COCs [3] - The lack of awareness leads to underutilization of COCs, which can provide both contraceptive and non-contraceptive health benefits [3] Group 3: Service and Distribution - Alibaba Health serves as a platform for the launch, providing a comprehensive online healthcare service system, including professional pharmacist reviews and medication guidance [4] - The platform addresses the inconvenience of purchasing medications due to time and geographical limitations, ensuring continuity of treatment through efficient nationwide delivery [4]

本报讯 （记者袁传玺）1月29日，拜耳原研口服避孕药优思悦®84片装大包装首批药品顺利完成进口通关，率先在阿里健 康首发，该规格于第八届中国国际进口博览会首次亮相，旨在覆盖三个月完整的用药周期，提升用药的便利性和依从性，更好 地契合女性健康长周期管理的实际需求。 复旦大学附属妇产科医院史颖莉教授说："对于临床诊断明确、治疗方案稳定、需长期药物支持的慢性病患者，经专业医 生评估后可开具长处方。避孕及痤疮治疗均需在医师指导下长期规范用药，一旦因购药不及时而中断，往往会影响疗效。优思 悦®84片装的推出，有助于减少频繁购药和不当停药的情况，提升患者依从性和用药连续性，为临床实践和患者管理提供了更 为便利的选择。" 优思悦®（屈螺酮炔雌醇片Ⅱ）是一种短效口服避孕药，2014年12月份在中国获批上市，是中国首个采用"24+4"给药模式 的复方口服避孕药，24片活性药片（每片含0.02mg炔雌醇和3mg屈螺酮）加4片无活性药片，适用于女性避孕，及≥14岁、没有 口服避孕药已知禁忌的已初潮女性的中度寻常痤疮治疗，只有在患者希望使用口服避孕药作为避孕措施时才能使用本品治疗痤 疮。优思悦®通过调节激素水平辅助治疗痤疮，通常至少 ...